Casas-Reza P, Gestal-Vázquez M, López-López D, Mato-Búa R

Language: Spanish
References: 9
Page: 153-155
PDF size: 209.56 Kb.

ABSTRACT

One of the most important adverse effects of neuroleptics is the possibility of triggering neuroleptic malignant syndrome (NMS). The diagnosis is determined by exclusion and the initial therapeutic management will be withdrawn by neuroleptics by the administration of benzodiazepines and, in extreme cases, the use of electroconvulsive therapy (ECT). ECT is an effective therapeutic option in these patients and in these cases a poor response to administration with antipsychotic drugs is obtained. Based on the case of the article "Rocuronium-sugammadex for the management of electroconvulsive therapy in neuroleptic malignant syndrome. A case report" where the successful management of the use of non-depolarizing relaxants and their specific reversal in electroconvulsive therapies in patients diagnosed with of malignant neuroleptic syndrome, we comment on the pathophysiology and anesthetic images as well as similarities with other hyperthermic entities, such as malignant hyperthermia.

REFERENCES

1. Nott MR, Watts JS. A fractured hip during electro-convulsive therapy. Eur J Anaesthesiol. 1999; 16: 265-267.

2. Sarpel Y, Togrul E, Herdem M, Tan I, Baytok G. Central acetabular fracture-dislocation following electroconvulsive therapy: report of two similar cases. J Trauma. 1996; 41: 342-344.

3. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164: 870-876.

4. Vargas A, Gómez-Restrepo C. Síndrome neuroléptico maligno. Rev Colomb Psiquiatr. 2007; 36: 101S-125S.

5. Casas RP, Gestal MV, Outeiro RA, López AS, Diéguez GP. Rocuronio-sugammadex para el manejo de la terapia electroconvulsiva en el síndrome neuroléptico maligno, a propósito de un caso. Rev Esp Anestesiol Reanim. 2017; 64: 105-107.

6. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 5th edition, DSM-5, Washington, DC: American Psychiatric Association, 2013.

7. González AG, Cortínez LI, De la Cuadra JC, Carrasco E, Rioseco A, Léniz P. Anestesia en terapia electroconvulsiva. Experiencia clínica. Rev Esp Anestesiol Reanim. 2007; 54: 414-420.

8. Fervienza A, López-Baamonde M, Jacas A, Muñoz G, Ibáñez C, Del Rio ME. Síndrome neuroléptico maligno en paciente postoperada: a propósito de un caso. Rev Esp Anestesiol Reanim. 2022; 69: 364-367.

9. Verdura VE, Ballesteros SD, Sanz-FJ. Terapia electroconvulsiva como tratamiento del síndrome neuroléptico maligno. Rev Psiquiatr Salud Ment. 2011; 4: 169-167.